Will Aurora Cannabis (TSX:ACB) Fall Below $1 in 2020?

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) went on a freefall in 2019. Will 2020 be better?

| More on:
edit Jars of marijuana

Image source: Getty Images

Investors who bought cannabis stocks in 2019 got burned badly, particularly those who bought Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB).

Starting the year at $7, it closed it out at just $2.50, making it one of the worst-performing marijuana stocks of 2019. After seeing several enormous losses, the stock fell out of investors’ favour early on and just kept tanking.

Now, the question is how much further the stock has to fall. With executives being forced out and European operations facing major headwinds, it seems unlikely that Aurora will recover significantly in 2020.

In the worst-case scenario, we might even see the stock fall below $1. To determine whether that will happen, we need to answer two main questions: can Aurora become profitable, and can it keep up its strong revenue growth?

Can it be profitable?

Profits have been a huge sticking point for marijuana stocks in general, and Aurora is no exception.

In its most recent quarter, Aurora had delivered positive net income of $10 million, but a loss from operations of $77 million. The operating loss was down from the same quarter a year before, but still large as a percentage of revenue.

As for the full 2019 fiscal year, the company lost $297 million (net) on top of other comprehensive losses of $72 million, bringing us to a whopping $370 million total comprehensive loss.

That’s far greater than the amount of revenue the company pulled in last year, so we’ll need to see some major changes before this company can become profitable.

Can it keep up its high growth?

Another big question for Aurora Cannabis shareholders is whether the company can continue its strong growth.

Over the past three years, Aurora has grown its net revenue by 190% CAGR. That’s a phenomenal annual growth rate, but it may slow down, for two reasons:

First, the company benefitted from the legalization of cannabis in 2018, creating an enormous revenue boost resulting from the introduction of a totally new revenue stream. When the company reported earnings all through last year, it was comparing quarters with this new revenue stream to prior year quarters when it didn’t exist.

Thus, the year-over-year revenue increase was predictably high. This year, however, the company will have to beat prior year quarters that also had legal cannabis, which will be much harder.

Second, Aurora is facing headwinds in Europe. The company recently lost its ability to sell medical cannabis in Germany, and while that problem is temporary, it will likely result in disappointing results when the company releases earnings in February.

Aurora also had some medical cannabis shipments to Italy cancelled. The shipments themselves were not that big, but the reasons cited for the cancellation (non-compliance with EU regulations) could foretell trouble to come.

Expect answers in February

For Aurora Cannabis investors, some clarity will be arriving in February, when the company releases earnings for the quarter ended December 31.

This report should provide a decisive answer as to whether profits are forthcoming, and whether revenue growth will decelerate in the wake of legalization’s one year anniversary.

It may also tell us how big of a hit the company will take from its European slip ups. If the worst-case scenario plays out, expect Aurora to slide even further.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »